Abstract
Aim: Our aim was to compare the outcome in subsequent frozen embryo replacement cycles in four groups of patients who had elective cryopreservation of all their embryos because they were considered to be at increased risk of developing severe ovarian hyperstimulation syndrome.
Design: Sixty-two (91%) of 68 IVF cycles (68 patients) in which elective cryopreservation of all embryos was performed were analyzed. All patients continued on the GnRH agonist, buserelin, after oocyte recovery until the onset of vaginal bleeding. Frozen embryo replacement occurred in a hormone replacement cycle that started either on day 3 of the withdrawal bleed (group I;N=15) or after serum estradiol levels had fallen to <100 pmol/L (group II;N=16). The other patients commenced a frozen embryo replacement cycle several months later in either a hormone replacement (group III;N=15) or a natural (group IV;N=16) cycle.
Results: Two patients developed severe ovarian hyperstimulation syndrome. There were no significant differences among the four groups regarding demographic variables, the dose of hMG used, and the clinical outcome. There was a higher but not significantly different clinical pregnancy rate in group I (26.7%), compared to group II (12.5%), group III (13.3%), and group IV (18.8%).
Conclusions: Several options exist for the timing and protocol used for frozen embryo replacement in patients who had elective cryopreservation for the prevention of ovarian hyperstimulation syndrome, none of which was found to be clearly superior in this observational report.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beral V, Doyle P, Tan S L, Mason B A, Campbell S: The outcome of pregnancies resulting from assisted conception. Br Med Bull 1990;46:753–768
Golan A, Weinraub Z, Ron-El R, Soffer Y, Herman A, Caspi E: Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 1988;50:912–916
MacDougall M J, Tan S L, Jacobs H S: In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992;7:597–600
Amso N N, Ahuja K K, Morris N, Shaw R W: The management of predicted ovarian hyperstimulation involving gonadotropin releasing hormone analog with elective cryopreservation of all pre-embryos. Fertil Steril 1990;53:1087–1090
Davies D W, Jenkins J M, Anthony F W, Gadd S C, Watson R H, Sakhrani L R, Masson G M: Biochemical monitoring during hormone replacement therapy cycles for transfer of cryopreserved embryos in patients with functional ovaries. Hum Reprod 1991;6:934–938
Wada I, Matson P L, Troup S A, Hughes S, Buck P, Lieberman B A: Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum Reprod 1992;7:962–966
Tan S L, Kingsland C, Campbell S, Mills C, Bradfield J, Alexander N, Yovich J, Jacobs H S: The long protocol of administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992;57:810–814
Schenker J G, Weinstein D: Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255–268
Kaaja R, Siegberg R, Titinen A, Koskimies A: Severe ovarian hyprestimulation and deep vein thrombosis. Lancet 1989;2:1043
Moses M, Bogowsky H, Anteby E, Lunenfeld B, Rabau E, Serr D, David A, Salomy M: Thromboembolic phenomena after ovarian stimulation with human menopausal gonadotrophin. Lancet 1965;2:1213
MacDougall M J, Tan S L, Balen A, Jacobs H S: A controlled study comparing patients with and without polycyctic ovaries undergoing in-vitro fertilisation. Hum Reprod 1993;8:233–237
Forman R G, Frydman R, Egan D, Ross C, Barlow D W: Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertil Steril 1990;53:502–509
Tan S L, Balen A, El Hussein E, Campbell S, Jacobs H S: The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in-vitro fertilization: A prospective randomized study. Fertil Steril 1992;58:378–383
Dahl Lyon C A, Wheeler C A, Frishman G N, Hackett R J, Seifer D B, Haning R V Jr: Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Hum Reprod 1994;9:792–799
Schenker J G: Prevention and treatment of ovarian hyperstimulation. Hum Reprod 1993;8:653–659
Asch R H, Ivery G, Goldman M, Fredercik J L, Stone S C, Balmaceda J P: Clinical report: The use of intravenous albumin in patients at risk of severe ovarian hyperstimulation syndrome. Hum Reprod 1993;8:1015–1020
Wada I, Matson P L, Troup S A, Morroll D R, Hunt L, Lieberman B A: Does elective cryopreservation of all embryos from women at risk of ovarian hyperstimulation syndrome reduce the incidence of the condition? Br J Obstet Gynaecol 1993;100:265–269
Pattinson H A, Hignett M, Dunphy B C, Fleetham J A: Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril 1994;62:1192–1196
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Awonuga, A.O., Dean, N., Zaidi, J. et al. Outcome of frozen embryo replacement cycles following elective cryopreservation of all embryos in women at risk of developing ovarian hyperstimulation syndrome. J Assist Reprod Genet 13, 293–297 (1996). https://doi.org/10.1007/BF02070141
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02070141